The latest talcum powder update is a proposed $5.5 billion deal for about 76,000 ovarian-cancer claims against Johnson & Johnson, according to Johnson & Johnson's Form 8-K. The deal is not final or automatic and needs support from at least 95% of remaining claimants, according to Nasdaq reporting on the announcement. The cases are grouped in federal multidistrict litigation, or MDL, a process that sends similar federal lawsuits to one judge for pretrial work.
That docket is MDL No. 2738 in New Jersey. This update covers the payment plan, case status, proof limits, and practical next steps.
Official resources:
- Explore the official data from Quotemedia — Use this primary source to review the underlying data.
- Read the official guidance from Wiley — Use this primary source to verify the official guidance.
Table of Contents
- How the $5.5 billion payout would work
- Where cases sit now
- What you still have to prove
- What claimants should do next
How the $5.5 billion payout would work
The July 27, 2026 proposal would resolve remaining ovarian-cancer talc claims in federal MDL 2738 and related state courts. It is a negotiated proposal, not a court order that pays everyone now.
First payment would be up to $3 billion in 2027, with the balance starting in 2028. Payment happens only if at least 95% of remaining claimants take part. If turnout falls short, the deal can fail and cases continue.
Where cases sit now
The federal talc docket remains the largest U.S. MDL, with 69,340 actions pending before Judge Michael Shipp on Oct. 1, 2026, according to the Judicial Panel statistics report. Size alone does not promise speed. It means filings, records, and bellwether picks stay under one court.
A faster bankruptcy path is closed. HMF Law's summary of the 57-page opinion says U.S. Bankruptcy Judge Christopher Lopez dismissed the Red River Talc LLC Chapter 11 plan on March 31, 2025. The court found the pre-filing claimant vote defective. Claims therefore stay in the MDL and state courts rather than moving to a bankruptcy trust.
What you still have to prove
J&J maintains its talc products do not cause cancer and admits no wrongdoing under the proposed settlement, according to Claims Journal coverage. A settlement payment is not a finding that powder caused any one person's illness. Outside researchers offer context, not case proof.
TortAdvisor's summary of IARC Monographs Vol. 136 says WHO's cancer agency classified talc as Group 2A, probably carcinogenic to humans. That label rested on limited ovarian-cancer evidence, sufficient animal evidence, and strong mechanistic data. Claimants who litigate still need personal proof such as diagnosis records, frequency and years of talc use, and expert causation evidence.
What claimants should do next
Product history matters because new bottles will not match old use. Johnson & Johnson Consumer Health said it discontinued talc-based JOHNSON'S Baby Powder globally in 2023. The portfolio moved to cornstarch-based powder. Keep old containers, photos, receipts, and a written use timeline if you have them. Testing rules also leave a gap.
Wiley Rein's alert says FDA withdrew its Dec. 27, 2024 proposal for standardized asbestos testing of talc cosmetics. The withdrawal took effect Nov. 28, 2025. No mandatory federal testing rule remains in place while future rulemaking is still required.
- Confirm your diagnosis, treatment dates, and years of talc powder use
- Save pathology reports, pharmacy records, product photos, and purchase proof
- Ask a talc attorney whether you are counted in MDL 2738 or a state case
- Ask about the 95% participation count, proof requirements, and response deadline
- Do not assume you are enrolled because you once registered interest